health new england glp 1 coverage Comparing Ozempic, Wegovy and Other GLP-1 Drugs June Update on Vida Health

Feeling Stuck

To stay ahead of this shifting environment, pharma companies should consider the following imperatives: Massive patient drop-off undermines obesity GLP-1 uptake: Despite strong demand, only 10% of obesity patients persist with therapy after one year

It is also used to reduce the risk of major cardiovascular events (such as heart attack, stroke, and cardiovascular death) in adults with type 2 diabetes and established heart disease

MAUD-T2D trial: Patients with T2D and markers of more severe AUD, comparing newer GLP-1 RAs to FDA-approved medications for AUD (MAUD: acamprosate, disulfiram, or naltrexone)